Keensight Capital Acquires Bedfont Scientific Ltd, Expanding MedTech

Keensight Capital has completed the acquisition of Bedfont Scientific Ltd, a specialist in exhaled breath and medical gas monitoring instruments, for an undisclosed amount.

This corporate transaction signifies Keensight Capital's investment in the medical diagnostics sector by taking ownership of the established company.

Bedfont Scientific, founded in 1976, is recognised for its innovative non-invasive breath analysis technology, serving both healthcare professionals and emergency services.

Bedfont Scientific's product portfolio includes the Smokerlyzer for smoking cessation, ToxCO for carbon monoxide poisoning screening, NObreath for asthma management, and the Gastrolyzer range for detecting gastrointestinal disorders and food intolerances.

The company also offers the Medi-Gas Check range for verifying the quality and quantity of piped medical gases.

With over 48 years of experience and a global distribution network of over 100 distributors, Bedfont Scientific has established itself as a leader in the field, advocating for breath analysis as a quick and non-invasive alternative to traditional testing methods.

The acquisition by Keensight Capital is strategically aimed at leveraging Bedfont Scientific's market position and technological expertise.

This move is expected to support and accelerate Bedfont's growth trajectory, enabling further innovation and expanded market reach for its diagnostic instruments.

Synergies are anticipated through combining Keensight Capital's investment acumen with Bedfont's product development capabilities and established global presence, reinforcing the company's commitment to advancing non-invasive medical diagnostics.

Looking ahead, the combined entity is poised to enhance its offerings and continue its mission of providing accessible and accurate breath testing solutions.

This acquisition is set to strengthen Bedfont Scientific's ability to innovate within the evolving healthcare landscape, ensuring the continued development and distribution of its vital monitoring instruments for improved patient care worldwide.